We describe the successful use of methadone in the restoration of sedation and provision of analgesia in two morphine-tolerant, paediatric patients who had suffered significant thermal injuries and were undergoing mechanical ventilation. Both patients had exhibited escalating requirements for sedative drugs while undergoing ventilation yet remained inadequately sedated. The introduction of i.v. methadone in place of i.v. morphine in the sedative regimen rapidly and effectively restored a state of sedation. Hyperalgesia and morphine tolerance appear to be associated; it is proposed that methadone acts primarily, under these circumstances, by re-establishing the analgesic state. Such use of methadone in the morphine-tolerant patient also afforded a concomitant sedativesparing effect. (Br. J. Anaesth. 1998; 80: 92-95) 
PATIENT NO. 1 An 18-month-old female, weighing 12 kg, was admitted to the regional paediatric intensive care unit (PICU) with 70% cutaneous burns of both partial and full thickness involving the face, neck, trunk and limbs. Additionally, there were airway burns and smoke inhalation injury. Tracheal intubation had been undertaken and intermittent positive pressure ventilation (IPPV) commenced before admission to the PICU; mechanical ventilation was continued throughout her admission. She underwent several surgical procedures of varying complexity for her burns. However, it became evident that survival would be most unlikely because of the severity of her initial injury and subsequent failure of skin engraftment. The child died on day 62. Throughout her stay in the PICU, her requirements for sedative drugs increased, gradually at first and then in a dramatic manner. The sedative regimen used, and the necessary changes made to it, are presented in table 1 .
On day 49, at the time of stopping the i.v. morphine infusion, blood sampling was performed for assay of concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide. The respective concentrations were subsequently reported as follows: morphine 202 nmol litre 91 , morphine-3-glucuronide 1308 nmol litre 91 and morphine-6-glucuronide 527 nmol litre 91 . PATIENT NO. 2 A 6-yr 2-month-old female, weighing 20 kg, was admitted to the regional PICU with 48% full thickness burns involving the trunk, waist, thighs and arms. Tracheal intubation had been undertaken and IPPV commenced before admission to the PICU; mechanical ventilation was continued. Subsequently, several surgical procedures were undertaken for her burn injuries. During her stay in the PICU, her sedative requirements escalated. The sedative regimen used, and the changes made to it, are presented in , methadone 20 mg i.v. bd and chloral hydrate 600 mg n.g. qds. Promethazine 12 mg n.g. qds was continued empirically for its antipruritic effect
Discussion
The most commonly identified goals of sedation in the paediatric intensive care unit are reduced patient distress, fewer unplanned extubations and facilitation of mechanical ventilation. 1 Optimal sedation of paediatric patients is considered difficult despite the use of frequent doses of many sedative agents. 1 Midazolam infusion has been shown to be an effective component in the sedation of the paediatric patient.
2-4 A significant disadvantage of the use of midazolam is the development of acute tolerance, 3 and it has been shown that there is increased clearance during continuous infusion. 4 Opioids are used for both their sedative and analgesic effects. It is well recognized that prolonged or frequent use of opioids is associated with the phenomenon of tolerance. Nevertheless, tolerance to opioids remains largely unexplained despite extensive interest in the underlying mechanism. Some factors are, however, evident; receptor occupancy is necessary for the development of tolerance, 5 both the mu and kappa receptors are affected, 6 7 continuous infusion of opioids produces more rapid tolerance than intermittent administration 8 and morphine tolerance develops without concurrent receptor downregulation. 9 Recent evidence suggests that mechanisms common to other forms of neuronal plasticity may mediate morphine tolerance. 10 Spinal cord N-methyl-D-aspartate receptor activation, [11] [12] subsequent protein kinase C translocation and activation, 13 and nitric oxide synthesis 12 may be involved. Additionally, altered metabolism of morphine leading to an increased ratio of morphine-3-glucuronide to morphine-6-glucuronide has been associated with uncontrolled nociceptive pain. 14 Interestingly, there appears to be significant similarities between the mechanisms of hyperalgesia and morphine tolerance. 10 In our patients with established morphine tolerance, with increasing doses of midazolam and additional sedative adjuvants being necessary, it was proposed that another opioid be given in place of morphine. Methadone was chosen for several reasons; it had been reported previously to be an effective analgesic in opioid-tolerant patients, [15] [16] [17] [18] it had been used successfully in treating iatrogenic opioid dependency in PICU patients, 19 it is known to be an effective analgesic after paediatric surgery 20 and it produces more prolonged respiratory depression in children than morphine. 21 In both patients, initial methadone administration produced rapid control of sedation. In patient No. 1, the need for sedative polypharmacy was reduced significantly and adequate sedation and analgesia were maintained at a considerably lower dose-equivalent with respect to morphine. An i.v. loading dose followed by i.v. infusion at the rate described did not produce haemodynamic instability. At discontinuation of the i.v. infusion, a thrice daily i.v. regimen was introduced. With the reduction in dosage of, or withdrawal of, other sedative agents, the daily dose of methadone administered was conservatively reduced. In patient No. 2, methadone was introduced as an initial twice daily bolus regimen on ceasing the i.v. infusion of morphine. Again, there was a considerably lowered dose-equivalent with respect to morphine. After tracheal extubation, methadone administration was changed from the i.v. to the enteral route. The existing daily dose of methadone was increased for two reasons: first, because of the simultaneous reduction in the daily dose of chloral hydrate and second, to make allowance for the fact that the oral bioavailability of methadone is reported to be 81%. 22 In both patients, the relatively long duration of action of methadone permitted twice or thrice daily dosing schedules.
Why can methadone be used successfully in the morphine-tolerant patient?
There is little doubt that there is incomplete cross-tolerance between morphine and methadone in animal models 23 24 and in the human population. 16 17 In the animal model, selective tolerance can be induced by selective agonists for all opioid receptor subtypes without any cross-tolerance occurring between the different receptor subtypes. 25 Methadone is a racemic mixture of laevorotatory (R9) and dextrorotatory (S9) isomers, with the analgesic activity of the racemate being a result almost entirely of the content of the Risomer. 26 There is stereospecific binding of methadone at the mu-1, mu-2 and delta receptors, with R9methadone having approximately 10-fold higher affinity than S9methadone. 26 Compared with morphine, R9methadone has approximately the same affinity for the mu-1, mu-2 and delta receptors, but has significantly lower affinity than morphine for the kappa receptor. However, methadone has higher intrinsic activity than morphine at the mu receptor. 
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The dose of i.v. morphine had been increased to 320 g kg 91 h 91 yet sedation remained inadequate. Therefore, it was decided to introduce methadone in place of morphine. The initial dose of methadone was 5 mg i.v. bd, the dose being administered over a period of 10 min 14
It was necessary to increase the dose of methadone to 5 mg i.v. tds 16 Increasing the daily dosage of methadone permitted a reduction in the dose of i.v. midazolam to 100 g kg 91 h 91
17
Weaning from mechanical ventilation was commenced. Midazolam was withdrawn, the dose of methadone reduced to 4 mg i.v. tds, and both promethazine and choral hydrate maintained at 12 mg n.g. qds, at 500 mg n.g. qds, respectively. Acceptable sedation was afforded by these doses 26
A further skin engraftment procedure led to the dose of methadone being restored to 5 mg i.v. tds 27
Mild agitation was apparent which responded readily to increasing chloral hydrate to 1 g n.g. qds 29
The trachea was extubated and the dose of methadone was switched from 5 mg i.v. tds to 8 mg n.g. tds; simultaneously, the dose of chloral hydrate was reduced to 500 mg n.g. qds and promethazine stopped. Spontaneous ventilatory function was deemed satisfactory. 36
The patient was discharged from the PICU to a high-dependency bed on the paediatric burns ward. She was awake and free from pain, being maintained on methadone 6 mg orally tds and chloral hydrate 500 mg orally at night
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In animal experiments, it has been demonstrated that the intrinsic activity of opioid agonists is inversely related to the degree of tolerance after continuous infusion. 28 Further work has shown that after establishing morphine tolerance, the potency of morphine is diminished whereas that of methadone is unaffected. 29 Thus the higher intrinsic activity of methadone compared with that of morphine is likely to be a key factor in incomplete opioid cross-tolerance.
Methadone has a chemical structure unrelated to that of morphine; methadone is a diphenylpropylamine whereas morphine is a phenanthrene. As a consequence of its structure, methadone inhibits 5-hydroxytryptamine (5-HT) and norepinephrine uptake whereas morphine does not, and it has been proposed that activity at the mu receptor and inhibition of both 5-HT and norepinephrine uptake combine to enhance the analgesic activity of compounds possessing these properties. 30 Morphine is metabolized to morphine-3-glucuronide and morphine-6-glucuronide; there is evidence that abnormal accumulation of M-3-G is associated with an antinociceptive effect. 15 31 The metabolites of methadone are pharmacologically inactive. 32 It must be noted that at discontinuation of i.v. morphine infusion in patient No. 1, the ratios of M-3-G to M-6-G and morphine were within the usual ratios compared with previously published paediatric pharmacokinetic data. 33 In opioid receptor pharmacology, it is considered that the kappa receptor mediates the inherent sedative properties of the opioid group of drugs. 34 It has been noted previously that morphine has a significantly greater affinity for the kappa receptor than either methadone isomer, 26 thus methadone has a markedly lesser inherent sedative action than morphine. Nevertheless, it has been reported that, in animal models where morphine tolerance has been induced, there is substantial tolerance to the pure kappa agonist U-50,488H 6 ; thus both mu and kappa receptor activities are altered in morphine tolerance. It is possible that methadone could restore agonist activity at the kappa receptor in morphine tolerance but it must be remembered that methadone has a low affinity for this receptor and any clinical effect under such circumstances is likely to be of little significance.
It appears that, under the circumstances of this case report, it was the restoration of analgesia with methadone that was the essential component of success in restoring sedation in morphine-tolerant patients. This correlates well with the postulate that hyperalgesia and morphine tolerance are associated.
When substituting methadone for morphine in the morphine-tolerant patient, the estimated dose of methadone to be administered must be made cautiously and on an individual basis. 16 For the two patients described, and in previously reported paediatric oncology patients with morphine tolerance, 16 17 it is noteworthy that after introduction of methadone, analgesia was maintained with significantly lower doses compared with those of morphine at the time of its termination.
